Schedule Today
(800)-221-4291

Same Day Service

Hair Follicle Drug Testing Abo, NM

Accredited Drug Testing Inc provides Hair Follicle drug testing Abo, NM for individuals and employers needing a drug test utilizing the hair follicle analysis process. To schedule a hair follicle drug test in Abo, NM, Call (800) 221-4291. Most testing centers are within minutes of your home or office.

Hair follicle drug testing Abo, NM is available for 5, 10, and 12 panel drug screenings.

To schedule a Hair Follicle Drug Test at one of our testing centers in the Grady county area, Call (800) 221-4291, Same Day Service Available. Testing centers do not require an appointment, but you must call and register for the test.

Hair follicle drug testing is becoming a more popular method by employers and individuals in need of a drug test due to the detection time frame being longer than a standard urine test.

Local Hair follicle drug testing Abo, NM centers are available to assist our clients throughout the entire process and all of our hair follicle drug testing Abo, NM facilities have certified drug testing technicians available to conduct a hair follicle drug test collection.

Hair Follicle Drug Test

In recent years the method to conduct drug testing has more frequently included a hair follicle drug test. Many employers, courts and Substance Abuse Professional are requiring a hair follicle drug test instead of a standard urine test. Hair follicle drug tests are used by employers who have zero tolerance drug use policies, courts and individuals on probation. The primary benefit of a hair follicle drug test include a much longer detection period for drug use which typically is up to 90 days. However, when screening drug use within the last 5 days the urine test continues to be the most accurate test.

Hair Follicle Drug Test Process

The procedure used to perform a hair follicle test is simple, the drug testing specialist will cut approximately 120 strands of hair (not really a lot) utilize a chain of custody procedure and send the hair to a certified laboratory for analysis. Drug testing centers require at least 1.5 inches of hair to perform this test and the hair generally needs to come from the head, however if the donor does not have head hair certain testing centers can use hair from chest, leg or arm pit.

If a donor has no hair on their body, than a hair test cannot be performed!

Hair Follicle Drug Test Results

Once the hair follicles have been analyzed by a certified laboratory they will then be reviewed and then verified by a Medical Review Officer (licensed Physician) who will than release the results. Generally a negative hair follicle drug test result is available in 2-3 days. A non-negative hair follicle drug test is available in approximately 5 days.

Urine cut-off levels are expressed in nanograms per milliliter (ng/mL) or as a weight of drug per unit volume of urine. Hair cut-off levels are expressed in picograms per milligram (pg/mg) or as a weight of drug per unit weight of hair

5 Panel Hair Follicle Drug Test

The 5 panel hair follicle drug test screens for the following


5 Panel w/ Expanded Opiates Hair Follicle Drug Test

The 5 panel w/ expanded Opiates hair drug test screens for the standard 5 drugs but will also screen for Opiate class drugs such as pain killers, which may indicate abuse of prescription drugs


10 Panel Hair Follicle Drug Test

The 10 panel hair follicle drug test screens for the following


12 Panel Hair Follicle Drug Test

The 12 panel hair follicle drug test screens for the following


To schedule a Hair follicle Drug Testing Abo, NM Call (800)221-4291.

Accredited Drug Testing Inc. is pleased to provide hair follicle drug testing, alcohol testing, occupational health and DNA testing services in Abo, NM.


When you need a test, choose the best!

Alcohol Testing Abo, NM Services

(800)221-4291

For more information regarding the effects of drug abuse – Click Here

For more information on a drug free work place – Click Here

Local Area Info: ABO (gene)

Histo-blood group ABO system transferase is an enzyme with glycosyltransferase activity, which is encoded by the ABO gene in humans. It is ubiquitously expressed in many tissues and cell types. ABO determines the ABO blood group of an individual by modifying the oligosaccharides on cell surface glycoproteins. Variations in the sequence of the protein between individuals determine the type of modification and the blood group. The ABO gene also contains one of 27 SNPs associated with increased risk of coronary artery disease.

The ABO gene resides on chromosome 9 at the band 9q34.2 and contains 7 exons. The ABO locus encodes three alleles. The A allele produces ?-1,3-N-acetylgalactosamine transferase (A-transferase), which catalyzes the transfer of GalNAc residues from the UDP-GalNAc donor nucleotide to the Gal residues of the acceptor H antigen, converting the H antigen into A antigen in A and AB individuals. The B allele encodes ?-1,3-galactosyl transferase (B-transferase), which catalyzes the transfer of Gal residues from the UDP-Gal donor nucleotide to the Gal residues of the acceptor H antigen, converting the H antigen into B antigen in B and AB individuals. Remarkably, the difference between the A and B glycosyltransferase enzymes is only four amino acids. The O allele lacks both enzymatic activities because of the frame shift caused by a deletion of guanine-258 in the gene which corresponds to a region near the N-terminus of the protein.This results in a frameshift and translation of an almost entirely different protein. This mutation results in a protein unable to modify oligosaccharides which end in fucose linked to galactose. Thus no A or B antigen is found in O individuals. This sugar combination is termed the H antigen. These antigens play an important role in the match of blood transfusion and organ transplantation. Other minor alleles have been found for this gene.

In human cells, the ABO alleles and their encoded glycosyltransferases have been described in several oncologic conditions. Using anti-GTA/GTB monoclonal antibodies, it was demonstrated that a loss of these enzymes was correlated to malignant bladder and oral epithelia. Furthermore, the expression of ABO blood group antigens in normal human tissues is dependent the type of differentiation of the epithelium. In most human carcinomas, including oral carcinoma, a significant event as part of the underlying mechanism is decreased expression of the A and B antigens. Several studies have observed that a relative down-regulation of GTA and GTB occurs in oral carcinomas in association with tumor development. More recently, a genome wide association study (GWAS) has identified variants in the ABO locus associated with susceptibility to pancreatic cancer.